Earnings summaries and quarterly performance for Pacira BioSciences.
Executive leadership at Pacira BioSciences.
Board of directors at Pacira BioSciences.
Research analysts who have asked questions during Pacira BioSciences earnings calls.
Hardik Parikh
JPMorgan Chase & Co.
5 questions for PCRX
Also covers: RPRX, VKTX
LS
Leszek Sulewski
Truist Securities
3 questions for PCRX
Also covers: AKBA, AMRX, ANIP +6 more
SB
Serge Belanger
Needham & Company
3 questions for PCRX
Also covers: AMPH, ARQT, BCRX +13 more
DT
Douglas Tsao
H.C. Wainwright & Co.
2 questions for PCRX
Also covers: ALKS, APLS, ARGX +21 more
Gary Nachman
Raymond James
2 questions for PCRX
Also covers: ABBV, ACHV, ADMA +9 more
LS
Les Sulewski
Truist
2 questions for PCRX
Also covers: AMRX, BHC, CRMD +2 more
OL
Oren Livnat
H.C. Wainwright
2 questions for PCRX
Also covers: ANIP, AVDL, CARA +7 more
AN
Anish Nikhanj
RBC Capital Markets
1 question for PCRX
Also covers: APTO, CRMD, EXEL +6 more
David Amsellem
Piper Sandler Companies
1 question for PCRX
Also covers: ABBV, ALKS, AMGN +28 more
Denis Reznik
Raymond James
1 question for PCRX
Also covers: AQST, INMB, VERU
DD
Dennis Ding
Jefferies Financial Group Inc.
1 question for PCRX
Also covers: ARDX, CARA, CRNX +10 more
DM
Douglas Miehm
RBC Capital Markets
1 question for PCRX
Also covers: ACB, AUPH, BHC +2 more
Gregory Renza
RBC Capital Markets
1 question for PCRX
Also covers: ACAD, ADCT, AGIO +12 more
JG
John Gionco
Needham & Co.
1 question for PCRX
Also covers: AMPH, CYTK, TRVI
TW
Tejas Wein
Raymond James
1 question for PCRX
Also covers: FOLD
Recent press releases and 8-K filings for PCRX.
Pacira BioSciences: DOMA Perpetual Seeks Board Changes and Company Sale
PCRX
Board Change
Executive Compensation
Takeover Bid
- DOMA Perpetual Capital Management LLC, which beneficially owns approximately 7.3% of Pacira BioSciences' outstanding shares, has nominated three director candidates to the company's Board of Directors.
- DOMA attributes Pacira's underperformance, including a 56% stock decline over the last decade and a 30% fall under CEO Frank Lee, to consistently missed earnings, lowered guidance, and a lack of profitability.
- DOMA is calling for the immediate replacement of CEO Frank Lee, the appointment of an interim CEO, and the initiation of a formal sale process for the business.
- The nominated candidates are Christopher Dennis, Oliver Benton Curtis III, and Eric de Armas, who bring expertise in healthcare, legal, corporate finance, risk management, and strategic capital allocation.
- DOMA criticizes the Board for approving wasteful expenditures and unsustainable executive compensation, noting that CEO Frank Lee's compensation in the last two years exceeded combined earnings per share distributed to all shareholders.
24 hours ago
Pacira BioSciences Responds to Director Nominations and Highlights 2025 Achievements
PCRX
Board Change
Share Buyback
Earnings
- Pacira BioSciences confirmed that DOMA Perpetual Capital Management LLC has nominated three director candidates for election to the Board at the 2026 Annual Meeting of Stockholders.
- The company highlighted significant progress on its 5x30 strategy, including treating 2.5 million patients with its products in 2025, increasing EXPAREL year-over-year volume growth to 6.2% in 2025, and achieving record-high 2025 GAAP and non-GAAP gross margins of 79% and 81%, respectively.
- In 2025, Pacira executed $150 million in common stock repurchases, reducing outstanding shares from 47 million to 41 million.
- The Board's Nominating, Governance and Sustainability Committee will review the proposed nominees, and shareholders are not required to take any action at this time.
1 day ago
Pacira BioSciences Discusses 2025 Performance, 2026 Outlook, and Strategic Initiatives
PCRX
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- Pacira BioSciences is progressing with its "five by thirty" strategy, which includes targets such as double-digit top-line growth and 5-point margin expansion. The company nearly achieved the 5-point margin expansion in 2025.
- The NOPAIN Act, implemented in January 2025, has positively impacted EXPAREL reimbursement for Medicare patients (ASP + 6%) and commercial payers (up to ASP + 29%). This contributed to EXPAREL volume growth of over 6% in 2025, compared to 3% in 2024.
- For 2026, the company expects total company revenue growth of 3%-6% and EXPAREL-specific revenue growth of 4%-8%.
- Key partnerships include an agreement with Johnson & Johnson MedTech to triple the reach of ZILRETTA, and with LG Chem for EXPAREL and ZILRETTA in Asia Pacific countries.
- The pipeline includes PCRX-201, a potential gene therapy for osteoarthritis, with Phase 2 Part A data expected by the end of 2026. The company also executed a share buyback in 2025 and maintains a strong financial position with capacity for M&A.
1 day ago
Pacira BioSciences Discusses 2025 Performance, 2026 Guidance, and Strategic Initiatives
PCRX
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Pacira BioSciences is executing its "Five by Thirty" strategy, aiming for double-digit top-line growth and a 5-point margin expansion by 2030. In 2025, EXPAREL volume grew north of 6% , driven by the NOPAIN Act, which provided Medicare reimbursement at ASP + 6% in outpatient settings, and commercial payers following suit with up to ASP + 29%.
- For 2026, the company expects total revenue growth of 3%-6%, with EXPAREL revenue growing 4%-8%. Key pipeline updates include the Phase 2 Part A readout for PCRX-201 (gene therapy for osteoarthritis) by the end of 2026 , and advancements for iovera and ZILRETTA.
- Strategic partnerships were established in 2025, including with Johnson & Johnson MedTech for ZILRETTA to triple its reach, and LG Chem for EXPAREL and ZILRETTA in Asia Pacific. The company maintains a strong financial position with low leverage and capacity for accretive business development deals.
1 day ago
Pacira BioSciences Provides Update on 5x30 Strategy, EXPAREL Performance, and 2026 Outlook
PCRX
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- Pacira BioSciences is progressing with its 5x30 strategy, aiming for double-digit top-line growth and a five-point margin expansion by 2030, having made substantial progress in 2025.
- EXPAREL achieved over 6% volume growth in 2025 and is projected to grow 4%-8% in 2026, significantly benefiting from the NOPAIN Act's reimbursement for Medicare patients at ASP + 6% and commercial payers offering up to ASP + 29%.
- The company anticipates total revenue growth of 3%-6% for 2026 and is advancing its pipeline, including PCRX-201 with Phase II part A data expected by the end of 2026, while also expanding market reach through partnerships with Johnson & Johnson MedTech for ZILRETTA and LG Chem for EXPAREL and ZILRETTA in Asia Pacific.
- Pacira maintains a strong financial position with low leverage, offering capacity for accretive business development, and conducted share buybacks in 2025.
1 day ago
Pacira BioSciences: DOMA Perpetual Nominates Director Candidates and Calls for CEO Replacement
PCRX
Board Change
Executive Compensation
Takeover Bid
- DOMA Perpetual Capital Management LLC, beneficially owning approximately 7.1% of Pacira BioSciences' outstanding shares, has nominated three director candidates to Pacira's Board of Directors.
- DOMA asserts that Pacira's stock has significantly underperformed, falling 56% over the last decade and 68% over the last 5 years, and 30% under CEO Frank Lee's leadership.
- DOMA criticizes the Board for a lack of financial controls and oversight, and for approving unsustainable executive compensation, noting that CEO Frank Lee's compensation in the last two years exceeded the combined earnings per share distributed to all shareholders.
- DOMA is calling for the immediate replacement of CEO Frank Lee, the appointment of an interim CEO, and a formal sale process of the business to maximize shareholder value.
2 days ago
Pacira BioSciences Reports Q4 and Full Year 2025 Results, Provides 2026 Guidance
PCRX
Earnings
Guidance Update
Share Buyback
- Pacira BioSciences reported Q4 2025 EXPAREL sales of $155.8 million, contributing to full-year 2025 revenue of $726 million and achieving the highest gross margins in company history.
- The company provided 2026 total revenue guidance of $745 million-$770 million, with EXPAREL sales projected at $600 million-$620 million.
- Strategic advancements include expanding EXPAREL coverage to 102 million lives outside the surgical bundle by the end of 2025, with exclusivity secured through 2039.
- In Q4 2025, Pacira executed $50 million in share repurchases, reducing outstanding shares to approximately 41 million, with $150 million remaining on the buyback authorization.
Feb 26, 2026, 9:30 PM
Pacira BioSciences Announces Q4 2025 Results and Strategic Growth Plan
PCRX
Earnings
Guidance Update
New Projects/Investments
- Pacira BioSciences reported $726 million in 2025 revenue and achieved a gross margin of 81%, with its products benefiting over 2.5 million patients.
- The company introduced its "5x30" growth strategy, aiming for double-digit compounded annual product revenue growth and gross margins of at least 81% by 2030, while expanding patient reach to over 3 million annually.
- Key strategic developments include a regional distribution agreement with LG Chem for EXPAREL in Asian-Pacific markets, with revenues anticipated from 2027.
- Commercial coverage for its products significantly expanded in 2025, reaching 102 million covered lives by Q4 2025.
- The pipeline highlights PCRX-201, a gene therapy for Knee OA, which demonstrated unprecedented pain relief and durability in Phase 1 trials and holds RMAT & ATMP designations.
Feb 26, 2026, 9:30 PM
Pacira BioSciences Reports Q4 and Full Year 2025 Results, Issues 2026 Guidance
PCRX
Earnings
Guidance Update
New Projects/Investments
- Pacira BioSciences reported Q4 2025 EXPAREL sales of $155.8 million and full-year 2025 revenue of $726 million, achieving the highest gross margins in its history.
- The company issued 2026 total revenue guidance of $745 million to $770 million, with EXPAREL sales projected at $600 million to $620 million, and non-GAAP gross margins expected between 77% and 79%.
- Strategic achievements include securing EXPAREL exclusivity through 2039, expanding commercial payer coverage to 102 million lives by the end of 2025, and advancing its pipeline with key clinical milestones for PCRX-201, PCRX-2002, and iovera expected in 2026.
- Pacira also returned capital to shareholders, executing $50 million in share repurchases during Q4 2025, reducing outstanding shares to approximately 41 million.
Feb 26, 2026, 9:30 PM
Pacira BioSciences Reports Strong FY 2025 Results and Issues 2026 Guidance
PCRX
Earnings
Guidance Update
Share Buyback
- Pacira BioSciences achieved $726 million in total revenue for full year 2025 and $155.8 million in EXPAREL sales for Q4 2025, with a non-GAAP gross margin of 80% for the quarter.
- The company provided 2026 full-year guidance, projecting total revenue between $745 million and $770 million, with EXPAREL sales expected to be $600 million to $620 million, and non-GAAP gross margins between 77% and 79%.
- Pacira significantly expanded EXPAREL market access, ending 2025 with 102 million lives covered outside the surgical bundle, which increased to 110 million in early 2026, and strengthened EXPAREL's IP runway through 2039.
- The company is advancing its pipeline with PCRX-201 and PCRX-2002, and has established strategic partnerships with LG Chem for ex-U.S. EXPAREL commercialization and J&J MedTech for ZILRETTA in the U.S..
- In Q4 2025, Pacira executed an additional $50 million in share repurchases, reducing outstanding shares to approximately $41 million, with $150 million remaining on its buyback authorization for 2026.
Feb 26, 2026, 9:30 PM
Quarterly earnings call transcripts for Pacira BioSciences.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more